Skip to content
Bored Studies
RecruitingAccepts healthy volunteersEarly Phase 1

Precision Dosing of Metformin in Youth With T2D

University of California, San Francisco · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT06120881

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 10–21 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Early Phase 1
Target enrollment
20
US sites recruiting
2
Study start
April 25, 2024
Record last updated
December 23, 2025

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The purpose of this study to compare the typically prescribed dose of metformin (1000mg twice a day) with a higher dose of metformin (1350mg twice a day).

Being studied: Metformin

Conditions: Type 2 Diabetes

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Age 10-21 years
  • Provider diagnosis of T2D
  • Stable medication regimen for 2 weeks before screening visit (No addition or removal of medications and no more than 20% change in insulin dose)
  • ≥ 1 month from T2D diagnosis
  • Taking regular metformin (not extended-release formula)
  • Ability to wear CGM for a total of 6 weeks while in the study.
  • English or Spanish speakers.
  • Willing to abide by recommendations and study procedures.
  • Willing and able to sign the Informed Consent Form (ICF) and/or has a parent or guardian willing and able to sign the ICF.
  • Participant and parent(s)/guardian(s) willingness to participate in all training sessions as directed by study staff. Written informed consent (and assent when applicable) obtained from subject or subject's legal representative and ability for subject to comply with the requirements of the study.

Exclusion Criteria

  • Pancreatic autoantibody positivity (GAD-65, insulin, IA-2, ICA 512, Zn-T8).
  • Known history of ongoing renal or hepatic disease.
  • Known history of significant mental illness or developmental delay impacting the ability to complete study activities independently.

Recruiting US locations

  • UCSF Benioff Children's Hospital Oakland, Pediatric Diabetes Clinic

    Oakland, CA 94609

    Site contact: Shylaja Srinivasan, MD · 415-353-9084 · Shylaja.Srinivasan@ucsf.edu

  • UCSF Benioff Children's Hospital San Francisco, Madison Clinic for Pediatric Diabetes

    San Francisco, CA 94158

    Site contact: Shylaja A Srinivasan, MD · 415-353-9084 · Shylaja.Srinivasan@ucsf.edu

Study contacts (from the official record)

  • Avani A Narayan, MS · 628-224-8364 · avani.narayan@ucsf.edu
  • Laura A. Dapkus Humphries, NCPT · 628-224-8364 · laura.dapkus@ucsf.edu
All diabetes studies in California →
Precision Dosing of Metformin in Youth With T2D (NCT06120881) | Bored Studies